← Leaderboards
Sharon L. Walsh
University Of Kentucky
$101,480,172
Attributed
$102,160,517
Total exposure
16
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $28.1M · FY2005–23$50M$37.5M$25M$12.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$102,160,517 · 16
By mechanism
UM1$81,731,115 · 1
R01$19,330,050 · 9
R56$400,189 · 1
P50$385,116 · 1
M01$192,276 · 3
R29$121,771 · 1
Top collaborators
- Sandra D. Comer1 shared
- Ronald N Marcus1 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Craig R Rush$27,535,139
- William Walton Stoops$15,269,484
- Audra L Stinchcomb$9,682,621
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsRandomizedHeroinDoseSafetyUnited StatesOpioidDouble-Blind MethodProceduresEnrollmentPlacebosPharmacodynamicsInpatientsBaseClinical ResearchAgonistMethadoneDesignVolunteerOxycodonePlacebo ControlLaboratoriesMarketingDependence
Grant awards (50)
Licit and Illicit Opioids: Comparative Studies in Humans$547,479
R01 · FY2023 · DA · contact PI
Kentucky CAN HEAL (Communities and Networks Helping End Addiction Long-term)$8,590,000
UM1 · FY2022 · DA · contact PI
Kentucky CAN HEAL (Communities and Networks Helping End Addiction Long-term)$27,502,167
UM1 · FY2021 · DA · contact PI
Licit and Illicit Opioids: Comparative Studies in Humans$586,640
R01 · FY2021 · DA · contact PI
Kentucky CAN HEAL (Communities and Networks Helping End Addiction Long-term)$25,249,958
UM1 · FY2020 · DA · contact PI
Licit and Illicit Opioids: Comparative Studies in Humans$641,136
R01 · FY2020 · DA · contact PI
Kentucky CAN HEAL (Communities and Networks Helping End Addiction Long-term)$20,388,990
UM1 · FY2019 · DA · contact PI
Licit and Illicit Opioids: Comparative Studies in Humans$642,294
R01 · FY2019 · DA · contact PI
Licit and Illicit Opioids: Comparative Studies in Humans$612,025
R01 · FY2018 · DA · contact PI
NK-1 Receptor Antagonism: A Role in Opioid Use Disorders$526,063
R01 · FY2018 · DA · contact PI
NK-1 Receptor Antagonism: A Role in Opioid Use Disorders$570,321
R01 · FY2017 · DA · contact PI
CERC-501 Kappa Antagonist for Nicotine Dependence$1,020,517
R01 · FY2016 · DA
NK-1 Receptor Antagonism: A Role in Opioid Use Disorders$568,605
R01 · FY2016 · DA · contact PI
NK-1 Receptor Antagonism: A Role in Opioid Use Disorders$530,534
R01 · FY2015 · DA · contact PI
Exploring New Drug Signals of Abuse in the Human Laboratory$400,189
R56 · FY2015 · DA · contact PI
Licit & Illicit Opioids: Comparative Studies in Humans$542,185
R01 · FY2014 · DA · contact PI
Evaluation of Novel Pharmacotherapies for the Treatment of Opioid Dependence$482,436
R01 · FY2014 · DA · contact PI
Licit & Illicit Opioids: Comparative Studies in Humans$522,636
R01 · FY2013 · DA · contact PI
Evaluation of Novel Pharmacotherapies for the Treatment of Opioid Dependence$501,384
R01 · FY2013 · DA · contact PI
Licit & Illicit Opioids: Comparative Studies in Humans$553,082
R01 · FY2012 · DA · contact PI
Licit & Illicit Opioids: Comparative Studies in Humans$501,064
R01 · FY2012 · DA · contact PI
Licit & Illicit Opioids: Comparative Studies in Humans$548,927
R01 · FY2011 · DA · contact PI
Licit & Illicit Opioids: Comparative Studies in Humans$557,582
R01 · FY2010 · DA · contact PI
New Neural Targets for Opioid Use Disorders: Human Studies$342,608
R01 · FY2010 · DA · contact PI
New Neural Targets for Opioid Use Disorders: Human Studies$342,199
R01 · FY2009 · DA · contact PI
Evaluation of Novel Treatments for Stimulant Dependence$617,144
R01 · FY2008 · DA · contact PI
Licit & Illicit Opioids: Comparative Studies in Humans$458,590
R01 · FY2008 · DA · contact PI
Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial$348,516
R01 · FY2008 · DA · contact PI
Evaluation of Novel Treatments for Stimulant Dependence$615,232
R01 · FY2007 · DA · contact PI
Licit & Illicit Opioids: Comparative Studies in Humans$491,594
R01 · FY2007 · DA · contact PI
Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial$355,629
R01 · FY2007 · DA · contact PI
EVALUATION OF NOVEL TREATMENTS FOR STIMULANT DEPENDENCE$123,681
M01 · FY2007 · RR · contact PI
LICIT AND ILLICIT OPIOIDS: COMPARATIVE STUDIES IN HUMANS: STUDY 1$55,222
M01 · FY2007 · RR · contact PI
Evaluation of Novel Treatments for Stimulant Dependence$629,029
R01 · FY2006 · DA · contact PI
Licit & Illicit Opioids: Comparative Studies in Humans$533,017
R01 · FY2006 · DA · contact PI
Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial$366,250
R01 · FY2006 · DA · contact PI
LICIT AND ILLICIT OPIOIDS: COMPARATIVE STUDIES IN HUMANS: STUDY 1$13,373
M01 · FY2006 · RR · contact PI
Licit &Illicit Opioids: Comparative Studies in Humans$448,647
R01 · FY2005 · DA
Factors in Drug Dependence$145,477
R01 · FY2005 · DA
Factors in Drug Dependence$564,525
R01 · FY2004 · DA
Licit &Illicit Opioids: Comparative Studies in Humans$455,879
R01 · FY2004 · DA
Factors in Drug Dependence$548,083
R01 · FY2003 · DA
Factors in Drug Dependence$532,120
R01 · FY2002 · DA
THERAPEUTIC POTENTIAL OF KAPPA-OPIOIDS AGAINST COCAINE$371,997
R01 · FY2002 · DA
NOVEL PHARMACOTHERAPIES FOR OPIOID WITHDRAWAL$0
P50 · FY2002 · DA
THERAPEUTIC POTENTIAL OF KAPPA-OPIOIDS AGAINST COCAINE$361,162
R01 · FY2001 · DA
NOVEL PHARMACOTHERAPIES FOR OPIOID WITHDRAWAL$0
P50 · FY2001 · DA
NOVEL PHARMACOTHERAPIES FOR OPIOID WITHDRAWAL$385,116
P50 · FY2000 · DA
THERAPEUTIC POTENTIAL OF KAPPA-OPIOIDS AGAINST COCAINE$347,442
R01 · FY2000 · DA
COCAINE WITHDRAWAL--HUMAN LABORATORY STUDIES$121,771
R29 · FY2000 · DA